55 related articles for article (PubMed ID: 1281668)
1. Serotonin and emesis--from animals to humans: a discussion of Professor Naylor's paper.
Cubeddu L; Hoffmann I; Fuenmayor N
Br J Cancer Suppl; 1992 Dec; 19():S9-11. PubMed ID: 1281668
[No Abstract] [Full Text] [Related]
2. Site(s) and mechanisms of the anti-emetic action of 5-HT3 receptor antagonists: a discussion of Professor Naylor's paper.
Tyers MB
Br J Cancer Suppl; 1992 Dec; 19():S12-3. PubMed ID: 1467194
[No Abstract] [Full Text] [Related]
3. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Malave JJ
Br J Cancer; 1992 Jul; 66(1):198-203. PubMed ID: 1379060
[TBL] [Abstract][Full Text] [Related]
4. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron.
Castejon AM; Paez X; Hernandez L; Cubeddu LX
J Pharmacol Exp Ther; 1999 Dec; 291(3):960-6. PubMed ID: 10565811
[TBL] [Abstract][Full Text] [Related]
5. DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.
Yoshida N; Omoya H; Ito T
J Pharmacol Exp Ther; 1992 Mar; 260(3):1159-65. PubMed ID: 1532032
[TBL] [Abstract][Full Text] [Related]
6. Emesis-related biochemical and histopathological changes induced by cisplatin in the ferret.
Endo T; Minami M; Monma Y; Saito H; Takeuchi M
J Toxicol Sci; 1990 Nov; 15(4):235-44. PubMed ID: 1707101
[TBL] [Abstract][Full Text] [Related]
7. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.
Cubeddu LX; O'Connor DT; Hoffmann I; Parmer RJ
Br J Cancer; 1995 Oct; 72(4):1033-8. PubMed ID: 7547218
[TBL] [Abstract][Full Text] [Related]
8. The role of serotonin as a mediator of emesis induced by different stimuli.
du Bois A; Kriesinger-Schroeder H; Meerpohl HG
Support Care Cancer; 1995 Sep; 3(5):285-90. PubMed ID: 8520873
[TBL] [Abstract][Full Text] [Related]
9. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy.
Cubeddu LX; O'Connor DT; Parmer RJ
J Clin Oncol; 1995 Mar; 13(3):681-7. PubMed ID: 7533826
[TBL] [Abstract][Full Text] [Related]
10. 5-hydroxytryptamine (5-HT) concentrations in the hippocampus, the hypothalamus and the medulla oblongata related to cisplatin-induced pica of rats.
Liu Y; Hamaue N; Endo T; Hirafuji M; Minami M
Res Commun Mol Pathol Pharmacol; 2003; 113-114():97-113. PubMed ID: 15686111
[TBL] [Abstract][Full Text] [Related]
11. Involvement of 5-HT1A and 5-HT2 receptor in cisplatin induced emesis in dogs.
Gupta YK; Sharma SS
Indian J Physiol Pharmacol; 2002 Oct; 46(4):463-7. PubMed ID: 12683222
[TBL] [Abstract][Full Text] [Related]
12. 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy.
Higa GM; Auber ML; Altaha R; Piktel D; Kurian S; Hobbs G; Landreth K
J Oncol Pharm Pract; 2006 Dec; 12(4):201-9. PubMed ID: 17156592
[TBL] [Abstract][Full Text] [Related]
13. Antiemetic activity of butorphanol against cisplatin-induced emesis in ferrets and dogs.
Schurig JE; Florczyk AP; Rose WC; Bradner WT
Cancer Treat Rep; 1982 Oct; 66(10):1831-5. PubMed ID: 6889914
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of cisplatin-induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987).
Ogilvie GK; Moore AS; Curtis CR
J Am Vet Med Assoc; 1989 Nov; 195(10):1399-403. PubMed ID: 2584105
[TBL] [Abstract][Full Text] [Related]
15. The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret.
Percie du Sert N; Rudd JA; Moss R; Andrews PL
Neurosci Lett; 2009 Nov; 465(1):16-20. PubMed ID: 19733218
[TBL] [Abstract][Full Text] [Related]
16. Action of (R)-sila-venlafaxine and reboxetine to antagonize cisplatin-induced acute and delayed emesis in the ferret.
Warneck JB; Cheng FH; Barnes MJ; Mills JS; Montana JG; Naylor RJ; Ngan MP; Wai MK; Daiss JO; Tacke R; Rudd JA
Toxicol Appl Pharmacol; 2008 Nov; 232(3):369-75. PubMed ID: 18675289
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological aspects of ipecac syrup (TJN-119)-induced emesis in ferrets.
Endo T; Nemoto M; Ogawa T; Tamakai H; Hamaue N; Hirafuji M; Takeda Y; Hasegawa M; Fugii Y; Minami M
Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):187-200. PubMed ID: 11913711
[TBL] [Abstract][Full Text] [Related]
18. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-induced emesis in the Ferret: a new animal model.
Florczyk AP; Schurig JE; Bradner WT
Cancer Treat Rep; 1982 Jan; 66(1):187-9. PubMed ID: 7198011
[TBL] [Abstract][Full Text] [Related]
20. BRL 43694, a new 5HT3 receptor antagonist, prevents cisplatin-induced emesis in dogs.
Bhandari P; Gupta YK; Seth SD
Methods Find Exp Clin Pharmacol; 1989 May; 11(5):361-3. PubMed ID: 2547129
[No Abstract] [Full Text] [Related]
[Next] [New Search]
